Akkermansia muciniphila (A. muciniphila)

The phrase "Akkermansia muciniphila abundance" refers not to a molecule or canonical therapeutic receptor, but instead to the relative or absolute quantity of the bacterium Akkermansia muciniphila present in a biological sample, typically within the gut microbiome. This is a measurement of the population of a bacterial species, not a molecular target. "Akkermansia muciniphila" is a Gram-negative, oval, strictly anaerobic, mucin-degrading bacterium colonizing the human gut, representing up to 3–5% of the total microbiome composition in healthy adults. Its abundance is considered a key indicator of gut health: high levels are associated with improved metabolic parameters, reduced inflammation, stronger gut barrier function, and favorable responses to anti-cancer immunotherapy. Reduced abundance correlates with obesity, type 2 diabetes, metabolic syndrome, and inflammatory diseases, while supplementation (either live or pasteurized bacterium) is under clinical investigation for several indications. Akkermansia abundance reflects the status of the mucosal niche—its depletion or enrichment, rather than the molecule itself, is often the actual biomarker of interest in studies of health, disease, and intervention trials. In summary: "Akkermansia muciniphila abundance" is not a canonical molecular target, but a microbiome measurement and biomarker. If you are seeking molecules that modulate this abundance, these would be drugs or dietary interventions, not direct ligands or antagonists of a traditional receptor, enzyme, or protein.

Other names

A. muciniphilaAkkermansia abundanceAkkermansia muciniphila levels

Not applicable for drugs directly targeting Akkermansia muciniphila abundance, but manipulation of its abundance can result in improved gut barrier function, reduction in inflammation, and improved insulin sensitivity via modulation of the mucin layer and gut hormones (GLP-1 induction).